Digital Pathology

The Ultimate Test: Does It Help Patients? After eighteen posts exploring the technical landscape of agentic omics—from foundation models for DNA and proteins to multi-agent systems for drug discovery—we arrive at the question that matters most: does any of this actually improve patient outcomes? The answer is more nuanced than the hype suggests. As of early 2026, the FDA has approved over 1,000 AI/ML-enabled medical devices, but only a small fraction operate on genomic or pathology data with demonstrated clinical utility (IntuitionLabs, 2025; Nature Digital Medicine, 2025). The gap between a model that achieves 95% accuracy on a benchmark and a tool that measurably extends survival remains wide—and crossing it requires navigating regulatory pathways, clinical validation studies, and the messy reality of healthcare IT infrastructure. ...

The Visible Layer of Biology While genomics reads the book of life and proteomics predicts the machinery that executes it, phenomics observes the actual outcome—the visible traits, cellular morphologies, and clinical presentations that emerge from the interplay of genes, environment, and chance. It is the layer we can see, measure, and often directly connect to disease. Yet phenomics has historically been the poor cousin of molecular omics. High-throughput sequencing transformed genomics and transcriptomics into data-rich disciplines, while phenotyping remained labor-intensive, subjective, and low-throughput. A pathologist examining tissue slides. A physician recording clinical observations. A biologist peering through a microscope. ...